RECRUITING

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Point-of-care ultrasound (POCUS) is the use of ultrasound by the bedside provider in real time to answer a specific question and guide medical management. POCUS can be used to diagnose the severity of neonatal respiratory distress syndrome (RDS) through a lung ultrasound score. Lung ultrasound scores have also been shown to predict if an infant is treated with an initial dose of surfactant. Therefore, using lung ultrasound scores to guide surfactant therapy for RDS will likely lead to earlier surfactant therapy and may improve short-term respiratory outcomes. This study will test this theory by comparing lung ultrasound score-guided surfactant therapy for premature infants with RDS with our current surfactant administration guidelines.

Official Title

Echography-guided Surfactant THERapy (ESTHER) For Preterm Infants With Respiratory Failure

Quick Facts

Study Start:2024-06-25
Study Completion:2025-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06446453

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:0 Hours to 2 Hours
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * The infant's parent/legal guardian can understand and willingly sign a written informed consent document for this study
  2. * Birth gestational age between 27w0d-36w6d
  3. * Diagnosis of respiratory failure secondary to RDS requiring respiratory support with non-invasive positive pressure ventilation
  1. * Unable to obtain lung ultrasound between 1-2 hours of life
  2. * Infants already intubated or received surfactant before the point of care lung ultrasound
  3. * Infants born with congenital cardiac disease, congenital lung disease, or congenital facial/airway malformations
  4. * Infants born with chromosomal abnormalities
  5. * Infants with APGARs ≤ 5 at 10 minutes of life
  6. * Infants requiring cardiopulmonary resuscitation or therapeutic hypothermia in the first 6 hours of life

Contacts and Locations

Study Contact

Jacob Kelner
CONTACT
860-545-9720
jkelner@connecticutchildrens.org

Principal Investigator

Jacob Kelner
PRINCIPAL_INVESTIGATOR
Connecticut Children's

Study Locations (Sites)

Connecticut Children's
Hartford, Connecticut, 06106
United States

Collaborators and Investigators

Sponsor: Connecticut Children's Medical Center

  • Jacob Kelner, PRINCIPAL_INVESTIGATOR, Connecticut Children's

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-25
Study Completion Date2025-05

Study Record Updates

Study Start Date2024-06-25
Study Completion Date2025-05

Terms related to this study

Additional Relevant MeSH Terms

  • Respiratory Distress Syndrome, Newborn
  • Pulmonary Surfactants
  • Intensive Care Units, Neonatal